ArticleCancers2026

Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer.

Giovanni Leuzzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.